Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity for pharmaceutical manufacturers in China. The drug-treatment rate for breast cancer has increased over the last few years in China owing to the launch of novel, premium-priced, targeted therapies (e.g., pertuzumab [Roche’s Perjeta]) and the inclusion of these agents in the National Reimbursement Drug List (NRDL). With a strong late-phase pipeline, we expect additional new agents to be launched, leading to further market growth during the forecast period. Additionally, with the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly encouraged to enter the breast cancer therapy market.


  • How large is China’s drug-treatable breast cancer population, and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s breast cancer market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  • What are the key market access considerations for key therapies in the breast cancer pipeline in China? What sales could they secure in breast cancer? What are interviewed experts’ opinions of the key emerging therapies?
  • What are the key drivers and constraints in the Chinese breast cancer market, and how will the market evolve over the forecast period?




Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with oncologists supported by survey data collected for this and other DRG research epidemiology. Includes the diagnosed incidence of breast cancer in urban versus rural China and clinically relevant and market-relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient shares of key breast cancer regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions


Phase III/PR:10+ drugs; Phase II: 10+ drugs; coverage of select preclinical and Phase I products


China in-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Table of contents

  • Breast Cancer - Geographic Focus: China - Breast Cancer - China In-Depth (China)
    • Breast Cancer - China In-Depth (China)

Author(s): Amardeep Singh, M.Pharma; Alexandre Vo Dupuy (PhamD, MSc)

Amardeep is a Senior Analyst in Decision Resources Group’s China-In-Depth team. In this role, he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.

Prior to joining Decision Resources Group, Amardeep has worked with WNS Global Services for more than 5 years, where he worked in commercial analytics team to support Respiratory franchise of one of the top ten global pharma company. He also worked with GlobalData for 1.5 years and authored the syndicated reports on Rare, Ophthalmology and Psychiatric disorders. He earned a master’s degree in Pharmaceutical Management from University of Delhi and Bachelor of Pharmacy from Guru Gobind Singh Indraprastha University (GGSIPU), New Delhi.


Alexandre joined Decision Resources Group in 2017 as an Associate Epidemiologist. He holds a PharmD from Paris Descartes University as well as a Master in pharmacoepidemiology from the University of Bordeaux. 

Prior to joining Decision Resources Group, he worked within the fields of Consulting and Real World Evidence, and as an intern within the Global Epidemiology department of one of the top pharmaceutical company. As an associate epidemiologist, Alexandre works across multiple disease areas estimating and forecasting incidence and prevalence, with a focus on cancer epidemiology.

Related Reports

Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast

The breast cancer therapy market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s...

View Details

Breast Cancer - Current Treatment - Detailed, Expanded Analysis (EU5)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

View Details

Breast Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (EU5)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Breast Cancer | Disease Landscape and Forecast | G7 | 2020

The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verze...

View Details